Sign In
Buy SPRC
$6.92
-0.0500 (-0.717%)
At Close: Jun 23, 2026
SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment
04:11pm, Monday, 19'th Aug 2024
The clinical trial for SCI-210 is conducted in Israel, after which the Company aims to move forward with the commercialization process of SCI-210, first in the Israeli market
Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy
07:51am, Monday, 19'th Aug 2024
Friday, SciSparc Ltd. SPRC signed an exclusive patent license agreement with Polyrizon Ltd to out-license its SCI-160 program to treat pain.
SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million
04:30pm, Friday, 16'th Aug 2024
SciSparc will receive consideration in shares, and in addition may receive cash payments and fees if certain development milestones are met
Why Is SciSparc (SPRC) Stock Up 94% Today?
08:09am, Thursday, 15'th Aug 2024
SciSparc (NASDAQ: SPRC ) stock is on the rise Thursday after the clinical-stage pharmaceutical company provided investors with an update concerning its AutoMax Motors merger. The big news here is The
SciSparc Updates Regarding the Status of the AutoMax Merger
04:53pm, Wednesday, 14'th Aug 2024
SciSparc provides investors with an update regarding the status of the merger agreement with AutoMax, including the court's approval of AutoMax's petition to convene special class meetings of its shar
SciSparc has been collaborating with Clearmind Medicine to create effective treatments for obesity and metabolic syndrome by combining SciSparc's Palmitoylethanolamide (PEA) with Clearmind's MEAI
SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer
08:20am, Monday, 22'nd Jul 2024
The discovery was demonstrated by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors
SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million
07:07am, Wednesday, 17'th Jul 2024
SciSparc will receive additional payments and execution fees if certain milestones are met
SciSparc Ltd. Announces Receipt of Nasdaq Minimum Bid Price Notification
11:55am, Tuesday, 16'th Jul 2024
TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare
Why Is SciSparc (SPRC) Stock Up 25% Today?
10:43am, Tuesday, 16'th Jul 2024
SciSparc (NASDAQ: SPRC ) stock is up on Tuesday after the clinical-stage pharmaceutical company announced a new patent application covering its weight loss treatment. SciSparc notes that this patent c
SciSparc Announces U.S. Patent Application for Treating Metabolic Syndrome and Weight Loss
06:03am, Tuesday, 16'th Jul 2024
TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies t
According to the agreement, SciSparc's pharmaceuticals assets are valued at approximately $11.6 million TEL AVIV, Israel, July 08, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company”
SciSparc Secures Strategic Advantage with Grant of European Patent
07:17am, Friday, 31'st May 2024
TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of ther
WASHINGTON--(BUSINESS WIRE)--New research provides resources for increasing 988 usage and access among populations disproportionately impacted by suicide and their loved ones.
SciSparc to Acquire AutoMax
08:15am, Thursday, 11'th Apr 2024
TEL AVIV, Israel, April 11, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies
